Ioannis E Koutroubakis
Overview
Explore the profile of Ioannis E Koutroubakis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
153
Citations
1869
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Orfanoudaki E, Foteinogiannopoulou K, Theodoraki E, Koutroubakis I
J Clin Med
. 2023 Apr;
12(7).
PMID: 37048536
Despite the evolution in inflammatory bowel disease (IBD) management during the last 20 years owing to the advent of new advanced therapies, anti-TNF agents still remain the cornerstone of therapy...
12.
Hashash J, Koutroumpakis F, Anderson A, Rivers C, Hosni M, Koutroubakis I, et al.
Ann Gastroenterol
. 2022 Nov;
35(6):609-617.
PMID: 36406970
Background: Serum protein reflects albumin and globulin levels, both of which can be altered in inflammatory bowel disease (IBD). The implications of a high globulin fraction in IBD are unknown....
13.
Theodoraki E, Orfanoudaki E, Petroulaki E, Foteinogiannopoulou K, Koutroubakis I
Eur J Gastroenterol Hepatol
. 2022 Sep;
35(1):15-20.
PMID: 36165073
Introduction: Smoking has been associated with lower levels of anti-TNF agents, higher antibodies and a reduced response to anti-TNF in patients with inflammatory bowel disease (IBD). The aim of this...
14.
Mantaka A, Galanakis N, Tsetis D, Koutroubakis I
Intest Res
. 2022 Aug;
20(4):495-505.
PMID: 35929091
Background/aims: Abdominal aortic calcium (AAC) deposition has been suggested as a marker of early atherosclerosis. There is no published data on the evaluation of AAC in inflammatory bowel disease (IBD)....
15.
Yanai H, Kagramanova A, Knyazev O, Sabino J, Haenen S, Mantzaris G, et al.
J Crohns Colitis
. 2022 Jul;
16(12):1882-1892.
PMID: 35895074
Background: Endoscopic-post-operative-recurrence [ePOR] in Crohn's disease [CD] after ileocecal resection [ICR] is a major concern. We aimed to evaluate the effectiveness of early prophylaxis with biologics and to compare anti-tumour...
16.
Zacharopoulou E, Orfanoudaki E, Tzouvala M, Tribonias G, Kokkotis G, Kitsou V, et al.
Inflamm Bowel Dis
. 2022 Apr;
29(2):228-237.
PMID: 35394529
Background: Four EMA-approved vaccines against SARS-CoV-2 are currently available. Data regarding antibody responses to initial vaccination regimens in patients with inflammatory bowel diseases (IBD) are limited. Methods: We conducted a...
17.
Caron B, Abreu M, Siegel C, Panaccione R, Sands B, Dignass A, et al.
Clin Gastroenterol Hepatol
. 2022 Feb;
20(11):2619-2627.e1.
PMID: 35189386
Background & Aims: Clinical trials evaluating biologics and small molecules in patients with ulcerative colitis are predominantly excluding ulcerative proctitis. The objective of the Definition and endpoints for ulcerative PROCtitis...
18.
Orfanoudaki E, Zacharopoulou E, Kitsou V, Karmiris K, Theodoropoulou A, Mantzaris G, et al.
J Clin Med
. 2022 Feb;
11(3).
PMID: 35160092
Since inflammatory bowel disease (IBD) patients were excluded from vaccine authorization studies, limited knowledge exists regarding perceptions and unfavorable effects of COVID-19 vaccination in this group. We aimed to investigate...
19.
Theodoraki E, Orfanoudaki E, Foteinogiannopoulou K, Andreou N, Gazouli M, Koutroubakis I
Int J Colorectal Dis
. 2022 Jan;
37(3):647-648.
PMID: 35092469
No abstract available.
20.
Mala A, Foteinogiannopoulou K, Koutroubakis I
World J Gastrointest Oncol
. 2022 Jan;
13(12):1956-1980.
PMID: 35070035
Malignancies constitute the second cause of death in patients with inflammatory bowel diseases (IBD), after cardiovascular diseases. Although it has been postulated that IBD patients are at greater risk of...